Chemical Compound

PRL-8-53

3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride

Evidence TierDWADA PROHIBITED

tuneTypical Dose

5 mg oral (single published study dose)

watchEffect Window

Acute verbal memory task context only. No data beyond single-session use.

lockCompliance

WADA PROHIBITED

Overview

Clinical Summary

PRL-8-53 is an experimental nootropic with extremely limited human research. It is used for short-term memory enhancement claims, but clinical validation and safety data are sparse.

A single small human study reported improved short-term memory recall, but replication is lacking. Mechanisms remain unclear, limiting confidence in targeted benefits. Minority anecdotal reports include improved focus and verbal fluency, which are not supported by controlled trials. Safety data for repeated or long-term use are insufficient, making net benefit highly uncertain and leaving the compound in a research-chemical category rather than an evidence-backed nootropic one.

Mechanism unknown. Speculated dopaminergic and cholinergic involvement based on early preclinical work, but never confirmed with receptor binding or imaging studies.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Improved verbal word retention in one double-blind trial (n=47, p<0.01)
  • No benefit on visual reaction time or motor control in same trial

Secondary Outcomes

  • Zero replication in 45+ years
  • Safety profile uncharacterized beyond single acute dose

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy
  • Lactation
  • Children/adolescents
  • Psychiatric conditions
  • Concurrent CNS-active medications
  • Seizure disorders

Side effects

  • None documented (single study did not report systematic adverse events)

Interactions

  • Unknown. Uncharacterized receptor pharmacology prevents prediction
  • Caution with dopaminergic and cholinergic agents (speculative mechanism)

Avoid if

  • High-risk cardiovascular conditions
  • Active psychosis or mania
  • Substance-use disorder
  • Severe hepatic or renal impairment

Evidence

Study-level References

prl-8-53-SRC-001Double-blind placebo-controlled clinical trial
Sourceopen_in_new

Hansl NR, Mead BT. "PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent." Psychopharmacology (Berl). 1978;56(3):249-53. PMID: 418433, DOI: 10.1007/BF00432846. URL: https://pubmed.ncbi.nlm.nih.gov/418433/

Population: Healthy adults (n=47)

Dose protocol: Oral PRL-8-53 (reportedly 5 mg) administered prior to verbal learning/retention task paradigm

Key findings: Retention improved significantly versus placebo (p<0.01 and p<0.001 in subgroup analyses). Acquisition showed modest improvement. Reaction time and motor control unchanged. Statistically significant verbal memory retention enhancement in a single acute session Effects most pronounced in subjects with initially poor recall baselines Non-verbal measures (reaction time, motor control) showed no benefit Study was designed, conducted, and published by the compound's inventor who held the patent

Notes: 4 This is the only published human study on PRL-8-53. The 5 mg dose is referenced in secondary literature but exact dosing detail is not fully transparent in the abstract. No replication has been attempted in 45+ years.

Paper content

Retention improved significantly versus placebo (p<0.01 and p<0.001 in subgroup analyses); acquisition showed modest improvement; reaction time and motor control unchanged Statistically significant verbal memory retention enhancement in a single acute session Effects most pronounced in subjects with initially poor recall baselines Non-verbal measures (reaction time, motor control) showed no benefit Study was designed, conducted, and published by the compound's inventor who held the patent

Guides

Setup

Help